Market Place
Sourcing Support
Incyte stops PhIII trial for PI3K inhibitor after primary endpoint failure
07 Mar 2023 //
ENDPTS
Incyte to discontinue late-stage trial for bone marrow cancer drug combination
04 Mar 2023 //
REUTERS
Incyte Provides Update on PIII LIMBER-304 Study of Parsaclisib and Ruxolitinib
03 Mar 2023 //
BUSINESSWIRE
Innovent Announces the NMPA in China Has Granted Priority Review to Parsaclisib
05 Jan 2023 //
PR NEWSWIRE
Incyte Announces Data from LIMBER Studies Evaluating Combination Treatments
10 Dec 2022 //
BUSINESSWIRE
Incyte pulls approval filing, following Gilead out of the exitIn
27 Jan 2022 //
FIERCEBIOTECH
Incyte Provides Update on Parsaclisib and MCLA-145
25 Jan 2022 //
BUSINESSWIRE
Innovent Announces Pivotal Phase 2 Results for Parsaclisib
13 Dec 2021 //
ASIAONE
Incyte Announces Updated Data Demonstrating Responses of Parsaclisib
11 Dec 2021 //
BUSINESSWIRE
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types
01 Nov 2021 //
PRESS RELEASE
Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid
07 Dec 2020 //
BUSINESSWIRE
Innovent Announces Parsaclisib Results in High Rate of Rapid and Durable
07 Dec 2020 //
PRNEWSWIRE
Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib
27 Apr 2020 //
PR NEWSWIRE
Incyte Scores Lucrative Deal For Its 3 Pipeline Products
27 Dec 2018 //
SEEKING ALPHA
Innovent, Incyte Licensing Agreement for 3 Clinical-stage Candidates in CN
21 Dec 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.